GRI BIO, Inc. financial data

Symbol
GRI on Nasdaq
Industry
Pharmaceutical Preparations
Location
2223 Avenida De La Playa, Suite 208, La Jolla, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Vallon Pharmaceuticals, Inc. (to 4/21/2023)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 212 %
Debt-to-equity 89.7 %
Return On Equity -331 % -147%
Return On Assets -174 % +48.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.93M shares -0.97%
Common Stock, Shares, Outstanding 802K shares -72.9%
Entity Public Float 9.5M USD +82.7%
Weighted Average Number of Shares Outstanding, Basic 458K shares +1524%
Weighted Average Number of Shares Outstanding, Diluted 458K shares +1524%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 4.05M USD -0.34%
General and Administrative Expense 4.57M USD -28.9%
Operating Income (Loss) -8.62M USD -36%
Net Income (Loss) Attributable to Parent -8.28M USD +28.1%
Earnings Per Share, Basic 221 USD/shares +97.9%
Earnings Per Share, Diluted 221 USD/shares +97.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.35M USD +32.4%
Cash, Cash Equivalents, and Short-term Investments 1.67M USD -67.8%
Assets, Current 6.88M USD +23.1%
Property, Plant and Equipment, Net 6K USD -33.3%
Operating Lease, Right-of-Use Asset 141K USD +244%
Other Assets, Noncurrent 0 USD -100%
Assets 7.03M USD +24.6%
Accounts Payable, Current 1.24M USD +303%
Employee-related Liabilities, Current 632K USD -26.7%
Accrued Liabilities, Current 935K USD -21.6%
Liabilities, Current 2.22M USD +38.2%
Operating Lease, Liability, Noncurrent 96K USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 2.31M USD +44.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -35.7M USD -30.2%
Stockholders' Equity Attributable to Parent 4.72M USD +16.9%
Liabilities and Equity 7.03M USD +24.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.2M USD -280%
Net Cash Provided by (Used in) Financing Activities 4.49M USD +336%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 802K shares -72.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.28M USD +406%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.35M USD +32.4%
Deferred Tax Assets, Valuation Allowance 14.5M USD +315%
Deferred Tax Assets, Gross 14.5M USD +313%
Operating Lease, Liability 14K USD -80.3%
Depreciation 1K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.78M USD +27.2%
Lessee, Operating Lease, Liability, to be Paid 14K USD
Property, Plant and Equipment, Gross 34K USD +3.03%
Operating Lease, Liability, Current 45K USD +9.76%
Lessee, Operating Lease, Liability, to be Paid, Year One 14K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 12.8M USD +300%
Share-based Payment Arrangement, Expense 436K USD +185%